Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support  Yago Nieto, Wilbur A Franklin, Roy B Jones, Scott I Berman, Julie Pellom, Anna E Barón, Elizabeth J Shpall  Biology of Blood and Marrow Transplantation  Volume 10, Issue 6, Pages 415-425 (June 2004) DOI: 10.1016/j.bbmt.2004.02.004

Figure 1 Differences in the outcome of OTC+ (n = 16) and OTC− (n = 226) HRPBC patients. A, EFS (P = .007); B, OS (P = .002). Biology of Blood and Marrow Transplantation 2004 10, 415-425DOI: (10.1016/j.bbmt.2004.02.004)

Figure 2 Differences in the outcome of OTC+ (n = 18) and OTC− (n = 93) MBC patients. A, EFS (P = .04); B, OS (P = .2). Biology of Blood and Marrow Transplantation 2004 10, 415-425DOI: (10.1016/j.bbmt.2004.02.004)